July 28, 2009 3:28 PM
- Text
Wyeth's Pristiq Launch is a Bust; Sales Numbers Not Noted
(MoneyWatch) Sales of Wyeth's antidepressant Pristiq were conspicuous by their absence in the company's Q2 2009 earnings report. Wyeth said only that Pristiq had "higher sales" but gave no numbers. The company was hoping Pristiq, which launched last year, would replace its $3.5 billion-a-year blockbuster Effexor, which went off-patent in 2008. Effexor sales were down 25 percent to $772 million.
It's a far cry from what people were saying two years ago. Reuters:
There are three things wrong with Pristiq, according to observers. First, it's a blatant patent extender. Even the drug's developer -- Dr. Michael Liebowitz, the Columbia University psychiatrist who led the major Pristiq trials -- isn't impressed with it, noted Daniel Carlat:
And, Dawdy adds, the drug has withdrawal symptoms that people don't like.
Here's a bulletin board for people taking Pristiq. As you can see, patients don't seem impressed.
It's a far cry from what people were saying two years ago. Reuters:
Some analysts have said Pristiq could post annual sales of up to $2 billion, if approved.That ain't happening. Leerink Swann estimates the drug earned sales of $67 million in 2008 and may get $260 million 2009. Those sales came after an ad campaign that compared depressed people to wind-up dolls (pictured).
There are three things wrong with Pristiq, according to observers. First, it's a blatant patent extender. Even the drug's developer -- Dr. Michael Liebowitz, the Columbia University psychiatrist who led the major Pristiq trials -- isn't impressed with it, noted Daniel Carlat:
Pristiq, he said, "is another SNRI -- it is not a revolutionary drug."Second, it generated a lot of adverse event reports in a short period of time, per Phil Dawdy, including 17 successful suicides.
And, Dawdy adds, the drug has withdrawal symptoms that people don't like.
Here's a bulletin board for people taking Pristiq. As you can see, patients don't seem impressed.
- Previously:
- Wyeth's Troubles: Ghostwriting to Be Revealed; Centrum Sales Weak
- Wyeth Q2: Ah! So That's Why Pfizer's Buying This Company
- Pfizer Offered $53 a Share for Wyeth; Wyeth Failed to Say Yes
- Wyeth, in Autism Case, Again Stars in Preemption Issue at Supreme Court
- Pfizer's Jet Sale: Downsizing or Upscaling? Wyeth Brings Its Own
- Wyeth's Own Vendors Gathered Evidence of Alleged Protonix Pricing Scam
- A Look Inside Pfizer's Corporate Jets, Now Up for Sale
- Wyeth CEO Got 69% Pay Raise; Was "Required" to Use Helicopter; Plus $24 Million Pfizer Sale Bonus
Latest Now in MoneyWatch
- Ohio unemployment hits 3-year-low
- Jill on Money: Retirement investing, allocation, long term care
- Could "web-lining" be dangerous?
- Insurers respond cautiously to contraceptive plan
- Judge: Legally, breastfeeding not related to pregnancy
- Budget deficit drops to $27 billion in January
- Why the Powerball Jackpot is part of my investment strategy
- Is the new VW Beetle diesel worth the money?
- Consumer sentiment highlights risks to recovery
- Valentine blues? 10 best cities to be single
- December trade deficit widens to $48.8 billion
- Alcatel-Lucent returns to profit in 2011
- 6 things never to say in a performance review
- $26B mortgage deal: Who gets the money?
- Friendly's CEO steps down
- Quarterly loss hits $3.3B at Postal Service
- Greeks rail against cuts as EU demands more
Latest CBS News Headlines
on Facebook
on CBS News
- Houston recalled as happy in days before death
- Pre-Grammy gala celebrates Whitney Houston's life
- The nation's weather
- Filmmaker Douglas Trumbull receives honorary Oscar
on Facebook
- Whitney Houston 1963-2012
- Adele sings a cappella for Anderson Cooper
- Remembering Whitney Houston 1963-2012
on CBS News






